The Manufacturers Life Insurance Company Takes Position in Alumis Inc. $ALMS

The Manufacturers Life Insurance Company purchased a new position in shares of Alumis Inc. (NASDAQ:ALMS) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 100,215 shares of the company’s stock, valued at approximately $2,820,000. The Manufacturers Life Insurance Company owned about 0.08% of Alumis at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Alumis by 64.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock valued at $77,000 after acquiring an additional 4,926 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Alumis by 24.0% during the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock worth $378,000 after acquiring an additional 11,949 shares during the last quarter. Jane Street Group LLC purchased a new stake in Alumis in the first quarter valued at $111,000. Rhumbline Advisers raised its position in Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after purchasing an additional 2,949 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Alumis by 163.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company’s stock valued at $3,504,000 after purchasing an additional 724,133 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ALMS shares. Morgan Stanley reissued an “overweight” rating and set a $39.00 price objective on shares of Alumis in a research report on Friday, May 15th. Wall Street Zen raised shares of Alumis from a “strong sell” rating to a “hold” rating in a research report on Sunday, August 23rd. Robert W. Baird set a $27.00 target price on shares of Alumis in a research note on Tuesday. Chardan Capital lifted their price target on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, May 19th. Finally, Citigroup reissued an “overweight” rating on shares of Alumis in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.73.

Alumis News Summary

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Alumis said patients with high interferon gene signature (IFNGS-high) showed robust responses, supporting plans to evaluate envudeucitinib in a smaller, biomarker-selected lupus population and potentially advance it into Phase 3. Alumis eyes late-stage lupus study despite trial miss
• Positive Sentiment: The company reported that envudeucitinib was generally well tolerated, with no new safety signals, reducing concerns that safety could prevent further development. Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in SLE
• Positive Sentiment: Alumis remains on track to submit a U.S. marketing application for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. That program remains the company’s main near-term commercial catalyst. Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
• Neutral Sentiment: Alumis discussed pharmacodynamic results suggesting activity in interferon-driven immune diseases, but the company is still a late-stage biotech without a commercial product, leaving valuation highly dependent on clinical and regulatory execution.
• Negative Sentiment: The LUMUS trial failed to meet both its primary and secondary endpoints in the overall SLE population. The broad lupus indication therefore appears less certain, prompting a more selective development approach. Alumis Phase 2b LUMUS Trial Misses Endpoints
• Negative Sentiment: The trial miss triggered an unusually large increase in put-option activity—4,619 puts versus typical volume of about 907—signaling heightened bearish positioning and volatility.

Insider Transactions at Alumis

In other Alumis news, insider David M. Goldstein sold 2,596 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $68,456.52. Following the sale, the insider directly owned 30,970 shares in the company, valued at $816,678.90. This represents a 7.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO John R. Schroer sold 3,282 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $86,546.34. Following the completion of the transaction, the chief financial officer directly owned 24,718 shares of the company’s stock, valued at $651,813.66. This represents a 11.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 19,953 shares of company stock valued at $534,311. 33.70% of the stock is owned by corporate insiders.

Alumis Price Performance

Shares of Alumis stock opened at $9.47 on Wednesday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -2.45 and a beta of -0.80. The business has a 50-day moving average of $26.20 and a 200 day moving average of $24.93. Alumis Inc. has a 12 month low of $3.76 and a 12 month high of $31.35.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). The business had revenue of $1.66 million for the quarter, compared to analysts’ expectations of $3.65 million. Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%. Equities research analysts anticipate that Alumis Inc. will post -2.95 earnings per share for the current year.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.